CL2008001162A1 - Compuestos derivados de piperidina, antagonista del receptor de taquiquinina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto para el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal, una enfermedad del sistema nervioso central. - Google Patents
Compuestos derivados de piperidina, antagonista del receptor de taquiquinina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto para el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal, una enfermedad del sistema nervioso central.Info
- Publication number
- CL2008001162A1 CL2008001162A1 CL2008001162A CL2008001162A CL2008001162A1 CL 2008001162 A1 CL2008001162 A1 CL 2008001162A1 CL 2008001162 A CL2008001162 A CL 2008001162A CL 2008001162 A CL2008001162 A CL 2008001162A CL 2008001162 A1 CL2008001162 A1 CL 2008001162A1
- Authority
- CL
- Chile
- Prior art keywords
- disease
- compounds
- piperidine
- compound
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Compuestos derivados de piperidina, antagonista del receptor de taquiquinina; composición farmacéutica que comprende a dichos compuestos; y uso del compuesto para el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal, una enfermedad del sistema nervioso central.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007114858 | 2007-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008001162A1 true CL2008001162A1 (es) | 2008-11-03 |
Family
ID=39926204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008001162A CL2008001162A1 (es) | 2007-04-24 | 2008-04-23 | Compuestos derivados de piperidina, antagonista del receptor de taquiquinina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto para el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal, una enfermedad del sistema nervioso central. |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080275085A1 (es) |
AR (1) | AR066267A1 (es) |
CL (1) | CL2008001162A1 (es) |
PE (1) | PE20090277A1 (es) |
TW (1) | TW200906408A (es) |
WO (1) | WO2008133344A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011195452A (ja) * | 2008-07-18 | 2011-10-06 | Taiho Yakuhin Kogyo Kk | アミド構造を有する新規ウラシル化合物又はその塩 |
EP2336105B9 (en) | 2008-09-19 | 2014-09-17 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound and use of same |
CN104185626A (zh) * | 2012-03-29 | 2014-12-03 | 东丽株式会社 | 3-哌啶甲酸衍生物和其药物用途 |
US10098350B2 (en) | 2013-04-15 | 2018-10-16 | E. I. Du Pont De Nemours And Company | Fungicidal amides |
US10399949B2 (en) | 2015-12-07 | 2019-09-03 | Kissei Pharmaceutical Co., Ltd. | NK1 receptor antagonist |
WO2024084360A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
WO2024084363A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Use of patatin-like phospholipase domain-containing protein 3 compounds |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2149767T5 (es) * | 1991-09-20 | 2005-06-16 | Glaxo Group Limited | Nuevo uso medico para antagonistas de taquiquininas. |
JP4068305B2 (ja) * | 1999-02-24 | 2008-03-26 | エフ.ホフマン−ラ ロシュ アーゲー | 3−フェニルピリジン誘導体、およびそのnk−1受容体拮抗薬としての用途 |
WO2003101964A1 (fr) * | 2002-05-31 | 2003-12-11 | Takeda Pharmaceutical Company Limited | Derive piperidine, procede de production, et utilisation |
EP1705176A4 (en) * | 2004-01-14 | 2009-06-03 | Takeda Pharmaceutical | CARBOXYLAMIDE DERIVATIVE AND ITS USE |
TW200606152A (en) * | 2004-07-02 | 2006-02-16 | Tanabe Seiyaku Co | Piperidine compound and process for preparing the same |
JP2007197428A (ja) * | 2005-12-28 | 2007-08-09 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
-
2008
- 2008-04-23 PE PE2008000700A patent/PE20090277A1/es not_active Application Discontinuation
- 2008-04-23 US US12/081,926 patent/US20080275085A1/en not_active Abandoned
- 2008-04-23 AR ARP080101711A patent/AR066267A1/es unknown
- 2008-04-23 WO PCT/JP2008/058304 patent/WO2008133344A2/en active Application Filing
- 2008-04-23 TW TW097114785A patent/TW200906408A/zh unknown
- 2008-04-23 CL CL2008001162A patent/CL2008001162A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW200906408A (en) | 2009-02-16 |
US20080275085A1 (en) | 2008-11-06 |
WO2008133344A2 (en) | 2008-11-06 |
WO2008133344A3 (en) | 2009-11-12 |
PE20090277A1 (es) | 2009-04-06 |
AR066267A1 (es) | 2009-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008003595A1 (es) | Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central. | |
CL2009000171A1 (es) | Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion. | |
CL2007002018A1 (es) | Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular. | |
CL2008002521A1 (es) | Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer. | |
CL2007002641A1 (es) | Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias. | |
CR10379A (es) | Composiones farmaceuticas de antagonistas del anticuerpo anti-cd40. | |
CL2008001162A1 (es) | Compuestos derivados de piperidina, antagonista del receptor de taquiquinina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto para el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal, una enfermedad del sistema nervioso central. | |
CL2007003192A1 (es) | Compuestos derivados de arilamidas sustituidas por tiazol u oxazol; composicion farmaceutica; y uso para el tratamiento de una enfermedad del tracto urinario. | |
CL2007003803A1 (es) | Compuestos derivados de sulfonamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer, dislipidemia, diabetes, obesidad, infeccion. | |
DK2311459T3 (da) | Manipulationsmodstandsdygtige orale, farmaceutiske doseringsformer indeholdende et opioidanalgetikum | |
CL2007003352A1 (es) | Compuestos derivados de heteromonociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades circulatorias, enfermedades metabolicas y/o enfermedades del sistema nervioso cen | |
ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
CL2007003604A1 (es) | Composicion farmaceutica para administrar oral que comprende el compuesto 17-aminogeldanamicina amorfo; y su uso en el tratamiento del cancer. | |
CL2008002162A1 (es) | Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras. | |
BRPI0810646A2 (pt) | " compostos farmacêuticos ". | |
CL2007002594A1 (es) | Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. . | |
CL2007002167A1 (es) | Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer. | |
CL2008001049A1 (es) | Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad. | |
CL2009000873A1 (es) | Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b | |
BRPI1009252A2 (pt) | composto, pró-droga, composição farmacêutica, métodos para prevenir ou tratar doenças do sistema nervoso central, e mal de alzheimer, e, uso do composto ou de uma pró-droga do mesmo | |
LTPA2019508I1 (lt) | Vaistų pristatymo sistema, skirta sunkiai vandenyje tirpstančių, farmaciškai aktyvių medžiagų, pateikimui | |
GT200600081A (es) | Derivados de acetilenno | |
UY30330A1 (es) | Nuevas formas polimorfas de (2s)-(4e)-n-metil-5-(3-(5-isopropoxipiridin)il)-4-penten-2-amina | |
CL2008000641A1 (es) | Compuestos derivados de amidas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del insomnio, disfuncion sexual, esquizofrenia, entre otras enferme | |
CL2007002479A1 (es) | Compuestos derivados de pirazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos tromboembolicos. |